IV fluids prevent renal failure in E Coli infections

Article

Giving children intravenous (IV) fluids early in the course of Escherichia coli infection appears to lower the odds of developing severe renal failure.

Giving children intravenous (IV) fluids early in the course of Escherichia coli infection appears to lower the odds of developing severe renal failure.

Researchers at Washington University School of Medicine in St Louis, Missouri, studied 50 children younger than 18 years from 11 pediatric hospitals in the United States and Scotland who were treated for diarrhea-associated hemolytic uremic syndrome (HUS). According to the researchers, 90% of the cases of diarrhea-associated HUS in North America occur in children younger than 18 years.

Of the 25 patients who received any IV fluids during the first 4 days of illness, 52% developed oligoanuric HUS compared with 84% who received no IV fluids. The risk of oligoanuria was 60% higher if no IV fluids were given during the first 4 pre-HUS days.

Clinical profiling can identify patients who might be infected with E coli and at risk of developing HUS, allowing for early use of IV volume expansion. Renal recovery cannot be hastened once oligoanuria is established, the researchers add.

Hickey CA, Beattie TJ, Cowieson J, et al. Early volume expansion during diarrhea and relative nephroprotection during subsequent hemolytic uremic syndrome. Arch Pediatr Adolesc Med. 2011. Epub ahead of print.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Recent Videos
Potential downstream benefits of RSV preventive measures, with Octavio Ramilo, MD
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Staphylococcus aureus risk in infants and neonatologist considerations with Aaron Milstone, MD
Octavio Ramilo, MD, reacts to the FDA approval of clesrovimab for RSV prevention | Image Credit: St. Jude Children's Research Hospital
Tina Tan, MD, comments on FDA expanded approval for MenQuadfi meningococcal disease vaccine
Tina Tan, MD, discusses impact of FDA's stricter COVID-19 vaccine policy for children
Related Content
© 2025 MJH Life Sciences

All rights reserved.